bioAffinity Technologies hosts CHEST presentation on CyPath Lung cancer risk assessment
BIAF•bioAffinity Technologies will sponsor a CHEST 2026 presentation on October 21 at the Phoenix Convention Center. Chief Medical Officer Gordon H. Downie will discuss CyPath Lung and preliminary research on an investigational test for asthma- and COPD-related lung inflammation.
1. CHEST presentation
bioAffinity Technologies will sponsor a CHEST 2026 presentation on October 21 at the Phoenix Convention Center. Chief Medical Officer Gordon H. Downie will discuss CyPath Lung’s role in lung cancer risk assessment and pulmonary nodule management, along with preliminary research on an investigational test for asthma- and COPD-related lung inflammation.
